A World Health Organization-backed plan to help speed innovation and share risks in developing Covid-19 treatments has provoked responses ranging from dismissal to outright disdain. Albert Bourla, the CEO of Pfizer, called it “nonsense” and “dangerous.” Gilead has apparently chosen to ignore it. Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, has said such plans add to companies’ options to give access to Covid-19 products, but later questioned whether another one was necessary.
https://thehealthcarestandard.com/wp-content/uploads/2020/02/Male-in-Pharmaceutical-Sciences-400x400-1.jpg 400 400 The Healthcare Standard http://thehealthcarestandard.com/wp-content/uploads/2019/07/The-Healthcare-Standard-750x50.png The Healthcare Standard2020-06-26 10:18:052020-06-26 10:20:00Pharma Companies Are Worried About Pooling Their IP. They Shouldn’t Be.